

- b) waiting for a time interval following the [administering] administration to permit the labeled antibody to preferentially concentrate at any cancerous site in the subject;
- c) determining background level; and
- d) detecting the labeled antibody in the subject, wherein detection of the labeled antibody above the background level indicates the presence of a cancer.

21. (amended) The method of Claim 20, 48 or 49 in which the subject is a human.

22. (amended) The method of Claim 20, 48 or 49 in which the labeled antibody is a monoclonal antibody.

23. (amended) The method of Claim 20, 48 or 49 in which the labeled antibody is a humanized antibody.

24. (amended) The method of Claim 20, 48 or 49 in which the labeled antibody is labeled with a radioisotope.

26. (amended) The method of Claim 20 or 48 in which time interval is 6 hours to 48 hours.

27. (amended) The method of Claim 20, 48 or 49 in which the labeled antibody is administered intravenously.

28. (amended) The method of Claim 20 which further comprises repeating steps (a) through (d) at monthly or yearly intervals.

29. (amended) A method for detecting cancer in a subject, comprising imaging said subject at a time interval after [administration] administering to said subject [of] an effective amount of a labeled antibody which specifically binds to C3b(i) or a labeled

antibody covalently linked to a second molecule which antibody specifically binds to C3b(i) [covalently linked to a second molecule], said time interval being sufficient to permit the labeled antibody to preferentially concentrate at any cancerous site in said subject, wherein detection of the labeled antibody localized at said site in the subject indicates the presence of cancer.

- Sub B3 cont
- a 2 cont
30. (amended) The method of Claim 29 or 50 in which the subject is a human.
31. (amended) The method of Claim 29 or 50 in which the labeled antibody is a monoclonal antibody.
32. (amended) The method of Claim 29 or 50 in which the labeled antibody is a humanized antibody.
33. (amended) The method of Claim 29 or 50 in which the labeled antibody is labeled with a radioisotope.
34. (amended) The method of Claim 29 or 50 in which time interval is 6 hours to 48 hours.

a 3

43. A kit comprising, in one or more containers, an antibody to C3b(i) or an antibody to C3b(i) covalently conjugated to a second molecule with instructions for use in the method of claim 20 or 29.

44. (amended) The kit of Claim [43] 48, 49 or 50 further comprising IgM or IgG antibody.
45. (amended) The kit of Claim [43 or 44] 48, 49 or 50 further comprising one or more complement components.

Add new claims 48-57, as follows:

- a 4 Sub B4
48. (new) A method for detecting cancer comprising:

- a) administering to a subject plasma, one or more complement components, IgG antibody or IgM antibody;
- b) administering to said subject an effective amount of a labeled antibody which specifically binds to C3b(i);
- c) waiting for a time interval following step (b) to permit the labeled antibody to preferentially concentrate at any cancerous site in the subject;
- d) determining background level; and
- e) detecting the labeled antibody in the subject, wherein detection of the labeled antibody above the background level indicates the presence of a cancer.

49. (new) A method for detecting cancer comprising:

- a) administering to a subject plasma, one or more complement components, IgG antibody or IgM antibody;
- b) waiting for a time interval following step (a);
- c) administering to said subject an effective amount of a labeled antibody which specifically binds to C3b(i);
- d) waiting for a time interval following step (c) to permit the labeled antibody to preferentially concentrate at any cancerous site in the subject;
- e) determining background level; and
- f) detecting the labeled antibody in the subject, wherein detection of the labeled antibody above the background level indicates the presence of a cancer.

50. (new) A method for detecting cancer in a subject, comprising imaging said subject at a time interval after administering sequentially to said subject plasma, one or more complement components, IgG antibody or IgM antibody and an effective amount of a labeled antibody which specifically binds to C3b(i), said time interval being sufficient to permit the labeled antibody to preferentially concentrate at any cancerous site in said subject, wherein

detection of the labeled antibody localized at said site in the subject indicates the presence of cancer.

51. (new) The method of Claim 20, 48 or 49 in which the labeled antibody is a human antibody.

52. (new) The method of Claim 29 or 50 in which the labeled antibody is a human antibody.

53. (new) The method of Claim 48 or 49 in which the plasma, IgG antibody or IgM antibody is administered intravenously.

54. (new) The method of Claim 48, 49 or 50 wherein at least one of the complement components is C3.

55. (new) The method of Claim 48 which further comprises repeating steps (a) through (e) at monthly or yearly intervals.

56. (new) The method of Claim 49 which further comprises repeating steps (a) through (f) at monthly or yearly intervals.

57. (new) A kit comprising, in one or more containers, an antibody to C3b(i) with instructions for use in the method of claim 48, 49 or 50.--

#### REMARKS

Claims 1-47 were pending in the instant application. Claims 1-19, 35-42, 46, and 47 have been canceled, without prejudice to Applicant's right to pursue the subject matter of the canceled claims in future applications. Claims 20-24, 26-34, and 43-45 have been amended and new claims 48-57 have been added to more particularly point out and distinctly claim the elected subject matter of the invention. Claims 20-34 and 43-57 are, therefore, pending in the instant application. A courtesy copy of the pending claims, as presently amended, is included herewith as Exhibit A.